GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

NLY01

Company
Johns Hopkins University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for NLY01 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07497399

    Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    Not yet reported Johns Hopkins University 120 participants Est. completion 2030-01 2 sites
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT03672604

    A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

    Not yet reported Neuraly, Inc. 96 participants Est. completion 2019-07-30 1 site
    Other conditions: Safety and Tolerability in Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT04154072

    A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

    Not yet reported Neuraly, Inc. 255 participants Est. completion 2023-02-14 61 sites
    Other conditions: Parkinson Disease
    View official trial listing →
  • Completed NCT NCT04159766

    A Study With NLY01 in Subjects With Type 2 Diabetes

    Not yet reported Neuraly, Inc. 20 participants Est. completion 2020-12-04 2 sites
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.